Dna X (SONM) Liabilities and Shareholders Equity (2018 - 2026)

Dna X's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 86.55% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.0 million (down 26.76% YoY) and the FY2025 annual result came in at $43.9 million, up 10.47% from the prior year.
• Liabilities and Shareholders Equity was $4.8 million for Q1 2026 at Dna X, down from $43.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $58.6 million in Q3 2023 and bottomed at $4.8 million in Q1 2026.
• A 5-year average of $43.2 million and a median of $43.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 44.11% — and 2026, when it tumbled 86.55%.
• Dna X's Liabilities and Shareholders Equity stood at $53.7 million in 2022, then increased by 4.39% to $56.0 million in 2023, then decreased by 29.09% to $39.7 million in 2024, then increased by 10.47% to $43.9 million in 2025, then tumbled by 88.98% to $4.8 million in 2026.
• Business Quant data shows SONM's Liabilities and Shareholders Equity at $4.8 million in Q1 2026, $43.9 million in Q4 2025, and $40.2 million in Q3 2025.